Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
TxCell SA today announces financial results for the first half of 2018 and provides an update on the proposed acquisition by Sangamo Therapeutics, Inc.
New Partnership Will Improve Orange County’s Healthcare Services
New York-based Y-mAbs Therapeutics will look at securing $96 million through an initial public offering to support development of its antibody-based therapeutic treatments for cancer.
Amicus Therapeutics, headquartered in Cranbury, New Jersey, inked a definitive agreement for 10 gene therapy programs licensed from Nationwide Children’s Hospital through the acquisition of Celenex.
Tesaro, Inc., an oncology-focused biopharmaceutical company, announced its participation in two upcoming investor conferences.
NOXXON Pharma N.V. announced today that the previously disclosed convertible bonds (see press releases of June 15 and August 1, 2018) have been listed on the Euronext Access market in Paris as notes convertible into NOXXON shares
Galapagos NV announced today the closing of its underwritten public offering of 2,961,373 American Depositary Shares (“ADSs”) at a price of $116.50 per ADS
Galapagos NV announces a share capital increase as a result of a public offering of American Depositary Shares.
Combined Company expected to drive growth and shareholder value with North America’s largest sales force, broadest product offering, and most efficient supply chain network in the industry
Expedeon AG said today that the management is not aware of any change in the operational or strategic position of the Company which would justify the recent movement in the share price.